Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Gastrointestinal Cancer
Erschienen in: Journal of Gastrointestinal Cancer 2/2020

24.07.2019 | Review Article

Associated Factors of Survival Rate and Screening for Colorectal Cancer in Iran: a Systematic Review

verfasst von: Hossein Mozafar Saadati, Farzad Khodamoradi, Hamid Salehiniya

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Colorectal cancer (CRC) is one of the most important cancers, which has various patterns in the world. The aim of this study was to determine the factor associated to survival and looking for screening in Iran.

Methods

A literature search was conducted using PubMed, Web of Science, Scopus, SID, and Magiran on June 30, 2018. Studies that performed survival analysis and the barrier of screening for colorectal cancer were included in this review.

Results

Fifty-three articles for survival and 11 for screening were included and examined. The important factors of survival are the age, cancer stage, tumor grade, ethnicity, marital status, family history of cancer, smoking, metastasis, and obesity. For barrier of screening, the cost, shame, fear of diagnosis the cancer, absence of clinical symptoms, and time limit were determined.

Conclusion

Remarkably, knowledge, attitude, and behaviors about CRC screening in Iran are very moderate to poor. According to diversity of survival rates and low tendency to screening, we need to further and deepen studies of barrier and facilitators of screening.
Literatur
1.
Ferlay J, Colombet M, Soerjomataram I. Global and regional estimates of the incidence and mortality for 38 cancers: GLOBOCAN 2018. Lyon: International Agency for Research on Cancer. World Health Organization; 2018.
2.
Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9(1):88.PubMedPubMedCentral
3.
Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, et al. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 2013;24(6):1207–22.PubMedPubMedCentral
4.
Forbes LJ, Warburton F, Richards M, Ramirez A. Risk factors for delay in symptomatic presentation: a survey of cancer patients. Br J Cancer. 2014;111(3):581–8.PubMedPubMedCentral
5.
Lyratzopoulos G, Abel G, Brown C, Rous B, Vernon S, Roland M, et al. Socio-demographic inequalities in stage of cancer diagnosis: evidence from patients with female breast, lung, colon, rectal, prostate, renal, bladder, melanoma, ovarian and endometrial cancer. Ann Oncol. 2012;24(3):843–50.PubMedPubMedCentral
6.
Rachet B, Ellis L, Maringe C, Chu T, Nur U, Quaresma M, et al. Socioeconomic inequalities in cancer survival in England after the NHS cancer plan. Br J Cancer. 2010;103(4):446–53.PubMedPubMedCentral
7.
Ramirez A, Westcombe A, Burgess C, Sutton S, Littlejohns P, Richards M. Factors predicting delayed presentation of symptomatic breast cancer: a systematic review. Lancet. 1999;353(9159):1127–31.PubMed
8.
Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58(3):130–60.PubMed
9.
Gany FM, Herrera AP, Avallone M, Changrani J. Attitudes, knowledge, and health-seeking behaviors of five immigrant minority communities in the prevention and screening of cancer: a focus group approach. Ethn Health. 2006;11(1):19–39.PubMed
10.
Maree JE, Wright SC. How would early detection be possible? An enquiry into cancer related knowledge, understanding and health seeking behaviour of urban black women in Tshwane, South Africa. Eur J Oncol Nurs. 2010;14(3):190–6.PubMed
11.
Faivre J, Bossard N, Jooste V. Trends in net survival from colon cancer in six European Latin countries: results from the SUDCAN population-based study. Eur J Cancer Prev : the official journal of the European Cancer Prevention Organisation (ECP). 2017;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study:S40–s47. https://​doi.​org/​10.​1097/​cej.​0000000000000293​.CrossRef
12.
Mengual-Ballester M, Pellicer-Franco E, Valero-Navarro G, Soria-Aledo V, García-Marín JA, Aguayo-Albasini JL. Increased survival and decreased recurrence in colorectal cancer patients diagnosed in a screening programme. Cancer Epidemiol. 2016;43:70–5.PubMed
13.
Wells G SB, O’Connell D, Peterson j, Welch V, Losos M (2000) The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis.
14.
Baghianimoghadam M, FATTAHI AM, Akhondi M, Mortazavizadeh M, Fallahzadeh H. Intention of colorectal cancer patients’ first degree relatives to screening based on planned behavior theory. TOLOO-E-BEHDASHT. 2012;10:13–22.
15.
Baghianimoghadam MH, Ardakani MF, Akhoundi M, Mortazavizadeh MR, Fallahzadeh MH, Baghianimoghadam B. Effect of education on knowledge, attitude and behavioral intention in family relative with colorectal cancer patients based on theory of planned behavior. Asian Pac J Cancer Prev. 2012;13(12):5995–8.PubMed
16.
Bidouei F, Abdolhosseini S, Jafarzadeh N, Izanloo A, Ghaffarzadehgan K, Abdolhosseini A, et al. Knowledge and perception toward colorectal cancer screening in east of Iran. Int J Health Policy Manag. 2014;3(1):11–5.PubMedPubMedCentral
17.
Salimzadeh H, Bishehsari F, Delavari A, Barzin G, Amani M, Majidi A, et al. Cancer risk awareness and screening uptake in individuals at higher risk for colon cancer: a cross-sectional study. BMJ Open. 2016;6(12):e013833.PubMedPubMedCentral
18.
Salimzadeh H, Bishehsari F, Sauvaget C, Amani M, Hamzehloo G, Nikfarjam A, et al. Feasibility of colon cancer screening by fecal immunochemical test in Iran. Arch Iran Med (AIM). 2017;20(12):726–33.
19.
Salimzadeh H, Delavari A, Montazeri A, Mirzazadeh A. Knowledge and practice of iranians toward colorectal cancer, and barriers to screening. Int J Prev Med. 2012;3(1):29.PubMedPubMedCentral
20.
Salimzadeh H, Eftekhar H, Majdzadeh R, Montazeri A, Shojaeizadeh D, Delavari A. More than half of senior residents in Tehran have never heard about colorectal cancer screening. Asian Pac J Cancer Prev. 2011;12(11):2851–6.PubMed
21.
Taheri-Kharameh Z, Noorizadeh F, Sangy S, Zamanian H, Shouri-Bidgoli AR, Oveisi H. Factors associated with adherence to colorectal cancer screening among moderate risk individuals in Iran. Asian Pac J Cancer Prev. 2015;16(18):8371–5.PubMed
22.
HA AS-BZTK, Sharififard F, Arani MS, Gol AHA, Sulmati MZ, Mirzaei S, et al. Evaluation of knowledge, attitude and practice of people over 50 years old toward colorectal cancer screening, based on health belief model. Qom Univ Med Sci J. 2015;9(1):59–65.
23.
Moattari M, SFM RM, Zare N, Sakina G. The effect of education based on health belief model on the knowledge and participation of at risk individuals in colorectal cancer screening. Res Med. 2008;33(1):47–54.
24.
Roozitalab M, GS MM, Mahdi SF, Zare N. The effect of health beliefs on university administrative staff participation in colorectal cancer screening programs-1383. Digestive journal. 2004;13(1):19–24.
25.
Moghimi DB, Safaei A, Zali MR. (2008)Survival rates and prognostic factors in colorectal cancer patients. Asian Pac J Cancer Prev. 2016;17(7):3575–81.
26.
Asghari Jafarabadi M, Hajizadeh E, Kazemnejad A, Fatemi S. Site-specific evaluation of prognostic factors on survival in Iranian colorectal cancer patients: a competing risks survival analysis. Asian Pac J Cancer Prev. 2009;10(5):815–21.PubMed
27.
Esna-ashari F, Sohrabi MR, Abadi AR, Mehrabian AA, Kolahi AA, Yavari P, et al. Colorectal cancer prevalence according to survival data in Iran in 2007. Pejouhesh dar Pezeshki (Research in Medicine). 2008;32(3):221–5.
28.
Moghimi-Dehkordi B, Safaee A, Zali MR. Comparison of colorectal and gastric cancer: survival and prognostic factors. Saudi J Gastroenterol: official journal of the Saudi Gastroenterology Association. 2009;15(1):18.
29.
Moradi A, Khayamzadeh M, Guya MM, Mirzaei HR, Salmanian R, Rakhsha A, et al. Survival of colorectal cancer in Iran. Asian Pac J Cancer Prev. 2009;10(4):583–6.PubMed
30.
Safaee AM-DB, Fatemi SR, Ghiasi S, Zali MR. Pathology and prognosis of colorectal cancer. Iran J Cancer Prev. 2009;2(3):137–41.
31.
Asghari Jafarabadi M, Hajizadeh E, Kazemnejad A, Fatemi S. Comparison the role of BMI, pathologic stage and hereditary related factors on survival between colon and rectal cancers: frailty competing risks model. Iran J Epidemiol. 2010;6(3):35–49.
32.
Safaee A, Moghimi-Dehkordi B, Fatemi S, Ghiasi S, Nemati-Malek F, Zali M. Characteristics of colorectal mucinous adenocarcinoma in Iran. Asian Pac J Cancer Prev. 2010;11(5):1373–5.PubMed
33.
Akhoond MR, Kazemnejad A, Hajizadeh E, GAnbary Motlagh A, Zali MR. Comparison of influential factors affecting survival of patients with colon and rectum cancer using competing risks model. Koomesh. 2011;12(2):119–28.
34.
Ghabeljoo M, Jafarabadi MA, Mohammadi SM, Hajizadeh E, Kazemnejad A, Fatemi SR. Patterns of survival for anatomical sites of colorectal cancer with shift to advanced lesions in Iran. Asian Pac J Cancer Prev. 2011;12(5):1225–31.PubMed
35.
Gohari MR, Biglarian A, Bakhshi E, Pourhoseingholi MA. Use of an artificial neural network to determine prognostic factors in colorectal cancer patients. Asian Pac J Cancer Prev. 2011;12(6):1469–72.PubMed
36.
Mehrabani D, Almasi-Hashiani A, Moshfeghi K, Khedmati E. Survival rate and its predictors in colorectal cancer patients, Southern Iran. Middle-East J Sci Res. 2012;12(8):1072–7.
37.
Aryaie M, Roshandel G, Semnani S, Asadi-Lari M, Aarabi M, Vakili MA, Kazemnejhad V, Sedaghat SM, Solaymani-Dodaran M (2013) Predictors of colorectal cancer survival in Golestan, Iran: a population-based study. Epidemiology and health 35.
38.
Heidarnia MA, Monfared ED, Akbari ME, Yavari P, Amanpour F, Mohseni M. Social determinants of health and 5-year survival of colorectal cancer. Asian Pac J Cancer Prev. 2013;14(9):5111–6.PubMed
39.
Akhavan A, Binesh F, Soltani A. Survival of rectal cancer in Yazd, Iran. Asian Pacific J Cancer Prev: APJCP. 2014;15(12):4857–60.
40.
Nosrati A, Naghshvar F, Torabizadeh Z, Salehi F. Correlation of colorectal cancer stem cell marker CD24 expression with clinicopathologic features and survival of patients with colorectal cancer. Govaresh. 2014;19(2):86–94.
41.
Ahmadi A, Mobasheri M, Hashemi Nazari SS. Survival time and relative risk of death in patients with colorectal cancer in an Iranian population: a cohort study. J Mazandaran Univ Med Sci. 2014;24(111):2–8.
42.
Fatemi SR, Pourhoseingholi MA, Asadi F, Vahedi M, Pasha S, Alizadeh L, et al. Recurrence and five-year survival in colorectal cancer patients after surgery. Iran J Cancer Prev. 2015;8(4).
43.
Semnani S, Noorafkan Z, Aryaie M, Sedaghat SM, Moghaddami A, Kazemnejhad V, et al. Determinants of healthcare utilisation and predictors of outcome in colorectal cancer patients from northern Iran. Eur J Cancer Care. 2016;25(2):318–23.
44.
Zargar A, Miroliaee A, Gooraji SA, Hajaghamohammadi A. Determination of effective factors on survival of GI cancers: results of five years follow up in Iranian population. Global J Health Sci. 2016;8(6):256.
45.
Mehrkhani F, Nasiri S, Donboli K, Meysamie A, Hedayat A. Prognostic factors in survival of colorectal cancer patients after surgery. Color Dis. 2009;11(2):157–61.
46.
Dianatinasab M, Ghaem H, Rezaianzadeh A, Hosseini SV, Khazraei H. Colorectal Cancer mortality in shiraz, Iran. Asian Pac J Cancer Prev. 2016;17(8):4101–5.PubMed
47.
Ghahremani R, Yavari P, Khodakarim S, Etemad K, Khosravi A. The estimated survival rates for colorectal cancer and related factors in Iran from 1384 to 1388 using the Aalen’s additive risk model. Iran J Epidemiol. 2016;11(4):20–9.
48.
Saki Malehi A, Hajizadeh E, Fatemi R. Evaluation of prognostic variables for classifying the survival in colorectal patients using the decision tree. Iran J Epidemiol. 2012;8(2):13–9.
49.
Mehrdad P, Masoud S, Edris S, Mehrnoush A. Mucinous and non-mucinous adenocarcinoma in colorectal cancer patients. Ann Oncol. 2017;28(3):75–9.
50.
Zahir ST, NazemianYazdi M, Arasteh P, Mortazavizadeh M, Karbalaeian M, ZareMehrjardi M. Clinicopathological features and survival rate of colorectal adenocarcinoma patients with and without a KRAS mutation: a five year study in Yazd, Iran. Asian Pacific J Cancer Prev: APJCP. 2016;17(7):3417–22.
51.
Zare-Bandamiri M, Khanjani N, Jahani Y, Mohammadianpanah M. Factors affecting survival in patients with colorectal cancer in Shiraz, Iran. Asian Pac J Cancer Prev. 2016;17(1):159–63.PubMed
52.
Madadizadeh F, Ghanbarnejad A, Ghavami V, Bandamiri MZ, Mohammadianpanah M. Applying additive hazards models for analyzing survival in patients with colorectal cancer in Fars Province, Southern Iran. Asian Pacific J Cancer Prev: APJCP. 2017;18(4):1077.
53.
Moamer S, Baghestani A, Pourhoseingholi MA, Hajizadeh N, Ahmadi F, Norouzinia M. Evaluation of prognostic factors effect on survival time in patients with colorectal cancer, based on Weibull Competing-Risks Model. Gastroenterol Hepatol Bed to Bench. 2017;10(1):54–9.
54.
Moamer S, Baghestani AR, Pourhoseingholi MA, Maboudi AAK, Shahsavari S, Zali MR, Majd TM (2017) Application of the parametric regression model with the four-parameter log-logistic distribution for determining of the effecting factors on the survival rate of colorectal cancer patients in the presence of competing risks. Iran Red Crescent Med J 19 (6).
55.
Rasouli MA, Moradi G, Roshani D, Nikkhoo B, Ghaderi E, Ghaytasi B. Prognostic factors and survival of colorectal cancer in Kurdistan province, Iran: a population-based study (2009–2014). Medicine. 2017;96(6):e5941.PubMedPubMedCentral
56.
Sanei B, Mahmoudieh M, Nasr-Esfahani M. Survival and recurrence time among patients with colon cancer reffered to Alzahra Hospital, Isfahan, Iran, during 2001-2010. J Isfahan Med Sch. 2017;35(431):598–608.
57.
Zare-Bandamiri M, Fararouei M, Zohourinia S, Daneshi N, Dianatinasab M. Risk factors predicting colorectal cancer recurrence following initial treatment: a 5-year cohort study. Asian Pacific J Cancer Prev: APJCP. 2017;18(9):2465–70.
58.
Esna-Ashari F, Sohrabi M, Abadi A, Mehrabian A, Mofid B, Bohluli M, et al. Colorectal cancer prevalence according to survival data in Iran-2007. Iran J Cancer Prev. 2012;2(1):15–8.
59.
Karimi ZA, Saadat A, Jalalian HR, Esmaeili M (2011) Epidemiology and survival analysis of colorectal cancer and its related factors.
60.
Ghadimi M, Mahmoodi M, Mohammad K, Zeraati H, Hosseini M, Sheikh Fathollahi M. Comparison of survival analysis of gastrointestinal Cancer patients using parametric and Cox models. J Sch Public Health Inst Public Health Res. 2010;8(2):1–14.
61.
62.
Roshanaei G, Komijani A, Sadighi A, Faradmal J (2014) Prediction of survival in patients with colorectal cancer referred to the Hamadan MRI center using of Weibull parameter model and determination of its risk factors during 2005-2013.
63.
Vakili M, Aghakoochak A, Pirdehghan A, Shiryazdy M, Saffarmoghadam A. The survival rate of patients with colorectal cancer in Yazd during 2001-2011. SSU_J. 2014;22(3):1187–95.
64.
Parsaee R, Fekri N, SHAHID SS, AFZAL AM, Shaarbaf EE, Esmaeily H (2015) Prognostic factors in the survival rate of colorectal cancer patients.
65.
Roudbari M, Abbasi ASL, Barfei F, Gohari MR, Khodabakhshi R. Survival analysis of colorectal cancer patients and its prognostic factors using cox regression. Razi J Med Sci. 2015;22(130):21–8.
66.
Moamar S, Baghestani AR, Pourhoseingholi MA, Maboudi AA (2016) Survival of patients with colorectal cancer based on parametric competing risk survival analysis.
67.
Abdolalian Z, Rafeie M, Baghestani A, Pourhosseingholi M, Daneshvar T. Analyzing the survival of colorectal cancer patients of Tehran Taleghani Hospital using non-mixture cure model. Arak Med Univ J (AMUJ). 2016;19:98–106.
68.
Atefeh Ghorbanzadeh LG AK, Kambiz Akhavan, Abbas Esmaeilzadeh, Ali Bahari, Ali Hadian Far (2016) Survival and its effective factors in patients with colorectal cancer referred to imam Reza hospital in 2005-2015.
69.
Rahimi Pordanjani S, Baeradeh N, Lotfi MH, Pourmohammadi B. Epidemiology of colorectal cancer: incidence, mortality, survival rates and risk factors. Razi J Med Sci. 2016;23(144):41–50.
70.
Ansari R, Amjadi H, Norozbeigi N, Zamani F, Mir-Nasseri S, Khaleghnejad A, et al. Survival analysis of colorectal cancer in patients underwent surgical operation in Shariati and Mehr Hospital-Tehran, in a retrospective study. Govaresh. 2007;12(1):7–15.
71.
Mehrkhani F, Nasiri S, Sorush A, Karamnezhad M, Mehrkhani F, Mosafa S, et al. Prognostic factors in the survival rate of colorectal cancer patients after surgery. Color Dis. 2010;11(2):157–61.
72.
Saedi H, Ghavamnasiri M, Toosi M, Homaei F, Roodbari S. The assessment of prognostic factors in patients with nonmetastatic rectal adenocarcinoma referred to Omid Hospital (Mashhad), Iran. J Gorgan Univ Med Sci. 2009;11(2):28–32.
73.
Mirhosseini SM, Fakhri M, Mozaffary A, Lotfaliany M, Behzadnia N, Ansari Aval Z, et al. Risk factors affecting the survival rate in patients with symptomatic pericardial effusion undergoing surgical intervention. Interact Cardiovasc Thorac Surg. 2012;16(4):495–500.PubMedPubMedCentral
74.
Baghestani AR, Daneshva T, Pourhoseingholi MA, Asadzadeh H. Survival of colorectal cancer in the presence of competing-risks-modeling by Weibull distribution. Asian Pac J Cancer Prev. 2016;17(3):1193–6.PubMed
75.
Yoosefi M, Baghestani AR, Pourhoseingholi MA, Baghban AA, Agha SHS, Zali MR. Evaluation of the survival time of the patients with colorectal cancer using exponential model. Govaresh. 2017;22(2):95–100.
76.
Abu-Helalah MA, Alshraideh HA, Abuseif A, Arqoob K, Ajaj A. Delay in presentation, diagnosis and treatment for colorectal cancer patients in Jordan. J Gastrointest Cancer. 2016;47(1):36–46.PubMed
Metadaten
Titel
Associated Factors of Survival Rate and Screening for Colorectal Cancer in Iran: a Systematic Review
verfasst von
Hossein Mozafar Saadati
Farzad Khodamoradi
Hamid Salehiniya
Publikationsdatum
24.07.2019
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 2/2020
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-019-00275-0

Weitere Artikel der Ausgabe 2/2020

Journal of Gastrointestinal Cancer 2/2020 Zur Ausgabe

Letter to the Editor

Hepatitis B Virus Infection and Susceptibility to Esophageal Cancer in China: Implications of Ethnicity-Related Interleukin-17 Gene Polymorphism?

Original Research

Patterns of Care and Outcomes of Adjuvant Chemoradiation for Node-Positive Pancreatic Adenocarcinoma

Invited Reviews

Immune Checkpoint Inhibitors in Locally Advanced, Unresectable, and Metastatic Upper Gastrointestinal Malignancies

Original Research

CpG Islands Methylation Analysis of CDH11, EphA5, and HS3ST2 Genes in Gastric Adenocarcinoma Patients

Case Report

Long-Term Survival in an Esophageal Cancer Patient with Multiple Recurrences

Review Article

Gut Microbiota as a Positive Potential Therapeutic Factor in Carcinogenesis: an Overview of Microbiota-Targeted Therapy

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise